Lightchain Capital

Recent News

C4-logo-400
November 20, 2023

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

READ MORE
Logo-Geneoscopy-400
November 14, 2023

Geneoscopy Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test

READ MORE
Logo-Geneoscopy-400
November 09, 2023

Noninvasive Multitarget Stool RNA Test Proves Sensitive for Colorectal Cancer, Advanced Adenomas

READ MORE
Logo-Geneoscopy-400
November 09, 2023

Don Hardison Appointed Chairman of the Board at Geneoscopy

READ MORE
wugen-logo-400
November 02, 2023

Wugen to Present New Clinical Data for WU-CART-007 and Preclinical Data for WU-NK-101, Two Investigational Allogeneic Cell Therapies for Challenging Hematologic Cancers, at American Society of Hematology Annual Meeting & Exposition

READ MORE
C4-logo-400
November 01, 2023

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

READ MORE
Logo-Geneoscopy-400
October 23, 2023

JAMA Publishes Geneoscopy’s Pivotal CRC-PREVENT Trial Results, Reporting Highest Sensitivity for Detecting Colorectal Cancer and Advanced Adenomas Among Available Noninvasive Screening Tests

READ MORE
C4-logo-400
October 11, 2023

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634,an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, andCFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myeloma and Non-Hodgkin’s Lymphoma

READ MORE
Logo-Geneoscopy-400
October 05, 2023

Geneoscopy to Present and Exhibit at American College of Gastroenterology 2023 Annual Meeting

READ MORE

Contact Us

Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131

 

LinkedIn

Submit

©2024 LIGHTCHAIN CAPITAL, LLC  All Rights Reserved | Privacy Policy
Website by Tidal Media Group